Patent Update: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: The search for inhibitors of the phospholipases A₂

References

• CONNOLLY S, ROBINSON DH: A new phospholipase Az comes to the surface. Drug News Perspect. (1993) 6(8): 584–590.
   Google Scholar
• GLASER KB, MOBILIO D, CHANG JY, SENrK0 N: Phospholipase Az enzymes: Regulation and inhibition. TiPS (1993)14(3): 92–98.
   PubMed Web of Science ®Google Scholar
• MAYER RJ, MARSHALL LA: New insights on mammalian phospholipase Az(s); comparison of arachidonoyl-se-lective and -nonselective enzymes. EASES J. (1993) 7(2): 339–348.
   Google Scholar
• GELB MH, JAIN MK, BERG OG: Inhibition of phospholipase Az. FASEB J. (1994) 802): 916–924.
   Google Scholar
• MOBILIO D, SCHIEHSER GA: Inhibitors of phospholipase A2. hl: Design of enzyme inhibitors as drugs. Sandler M, Smith FU (Eds.), Oxford University Press (1994) pp 648–671.
   Google Scholar
• KRAMER RM, SHARP JD: Recent insights into the structure, function and biology of cPLA2. In: Novel molecular approaches to anti-inflammatory therapy. Pruzanski W, Vadas P (Eds.) Agents and Actions Suppl. 46, Birkhauser Verlag, Basel (1995) pp 65–76.
   Google Scholar
• DENNIS EA: Diversity of group types, regulation, and function of phospholipase Az. J. Biol. Chem. (1994) 269(18): 13057–13060.
   PubMed Web of Science ®Google Scholar
• All of the above are complementary reviews which cover all major aspects of PLA2 research to date.
   Google Scholar
• CONNOLLY S, ROBINSON DH: Patent Update: Inhibitors of the phospholipases A. Curr. Opin. Thera. Patents (1993) 3(8): 1141–1155.
   Google Scholar
• Critical review of the PLA2 patent literature published between 1992 arid 1993.
   Google Scholar
• TRIMBLE LA, STREET IP, PERRIER H, TREMBLAY NM,WEECH PK, BERNSTEIN MA: NMR structural studies of the tight complex between a trilluoromethyl ketone Inhibitor and the 85-kDa human phospholipase A2. Biochemistry (1993) 32(47): 12560–12565.
   PubMedGoogle Scholar
• Spectroscopic evidence that the trifluoromethyl ketone inhibitor forms a charged hemiketal (probably with a catalytic serine residue) at the active site of cPLA2.
   Google Scholar
• BARTOLI F, UN H-K, GHOMASHCHI F, GELB MEL JAIN MK, APITZ-CASTRO R: Tight binding inhibitors of 85-1cDa phospholipase A2 but not 14-kDa phospholipase Az Inhibit release of free arachidonate in thrombin-stimu-lated human platelets. J. Biol. Chem. (1994) 269(22): 15625–15630.
   Google Scholar
• R1ENDEAU D, GUAY J, WEECH PK, LALIBERTE F, YERGEYJ, U C, DESMARALS S, PERRIER H, LIU S, NICOLL-GRIFFITH D, STREET IP: Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase Az, blocks production of arachidonate and 12-hydroxyei-cosatetraenoic acid by calcium ionophore-challenged platelets. J. Biol. Chem. (1994) 269(22): 15619–15624.
   PubMedGoogle Scholar
• References 10 and 11 are complementary papers which provide some of the first evidence for the role of cPLA2 in the generation of lipid mediators in certain cell types.
   Google Scholar
• ROSHAK A, SATHE G, MARSHALL LA: Suppression of monocyte 85-1cDa phospholipase Az by antisense and effects on endotoxin-induced prostagi2ndin biosynthe-sis. J. Biol. Chem. (1994) 269(42): 25999–26005.
   PubMed Web of Science ®Google Scholar
• BERENBAUM F, THOMAS G, POIRAUDEAU S, BEREZIAT G, CORVOL MT, MASLIAH J: Insulin-like growth factors counteract the effect of interleukin 113 on type II phos-pholipase Az expression and arachiclonic acid release by rabbit articular chondrocytes. FEBS Lett. (1994) 340(1,2): 51–55.
   Google Scholar
• PFEIISCHIliIER J, SCHALICWIJK C, BRINER VA, VAN DEN BOSCH H: Contribution of group II phospholipase Az to arachiclonic add release and prostaglandin synthesis by mesangial cells. Agents and Actions (1994) Special Conference Issue 41: C150–C152.
   Google Scholar
• FONTEH AN, BASS DA, MARSHALL LA, SEEDS M, SAMETJM, CHILTON FH: Evidence that secretory phospholipase A2 plays a role in arachidonic add release and ei-cosanoid biosynthesis by mast cells. J Immunol. (1994) 152(11): 5438–5446.
   PubMedGoogle Scholar
• HUNDLEY TR, HUBBARD WC, MACGLASHAN DW: Arachi-donic acid release for leukotriene C4 (LTC) synthesis in human basophils is mediated by a secretory phospholi-pase Ay. FASEBJ. (1995) 9(3): A225.
   Google Scholar
• MARSHALL LA, WINKLER JD, GRISWOLD DE, BOLOGNESE B. ROSHAK A, SUNG CM, WEBB EF, JACOBS R: Effects of scalaradial, a type II phospholipase A2 inhibitor, on human neutrophil arachidonic add mobilisation and lipid mediator formation. J. Pharmacol. Exp. 7her. (1994) 268(2): 709–717.
   Google Scholar
• LEHMAN JJ, BROWN KA, RAMANADHAM S, TuRic j, GROSSRW: Arachidonic acid release from aortic smooth mus-cle cells induced by [Are] vasopressin is largely medi-ated by calcium-independent phospholipase Az. J. Biol. Chem. (1993) 268(28): 20713–20716.
   PubMedGoogle Scholar
• KISHINO J, KAWAMOTO K, ISHIZAKI J, VERHEIJ HM, OHARA 0, ARITA H: Pancreatic-type phospholipase A2 activates prostaglandin E-2 production in rat mesangial cells by receptor binding reaction. J. Biochem. (1995) 117(2): 420–424.
   PubMedGoogle Scholar
• ACKERMANN EJ, CONDE-FRIEBOES K, DENNIS EA: Inhibition of macrophage Ca2.-independent phospholipase Az by bromoenol lactone and trifluoromethyl ketones. J. Biol. Chem. (1995) 270(1): 445–450.
   Google Scholar
• REYNOLDS U, HUGHES LL, YU L, DENNIS EA: 1-Ilexadecy1-2-arachidonoylthio-2-deoxy-sn -glycero-3-phosphorykholine as a substrate for the microtiter-plate assay of human cytosolic phospholipase A2. Anal. Biochem. (1994) 217(1): 25–32.
   PubMedGoogle Scholar
• HUANG Z, LALIBERTE F, TREMBLAY NM, VITEECH PK, STREET IF: A continuous fluorescence-based assay for the human high-molecular-weight cytosolic phospholi-pase A2. Anal. Biochem. (1994) 222(1): 110–115.
   PubMedGoogle Scholar
• GENISSON Y, TYLER PC, YOUNG RN: Total synthesis of (+/-)-thielocin A113: A novel inhibitor of phospholipase A2../. Am. Chem. Soc. (1994) 116(2): 759–760.
   Google Scholar
• MATSUMOTO K, TANAKA K, MATSUIANI S, SAKAZAKI R, HINO0 II, UOTANI N, TANIMOTO T, KAWAMURA Y, NAKAMOTO S, YOSHIDA T: Isolation and biological activity of thielocins: Novel phospholipase Az inhibi-tors produced by Thielavia terricola RF-143./ Antibiot-ics (1995) 48(2): 106–112.
   Google Scholar
• WHEELER TN, BLANCHARD SG, ANDREWS RC, FANG F,GRAY-NUNEZ Y, HARRIS CO, LAMBERT MH, MEHROTRA MM, PARKS DJ, RAY JA, SMALLEY TL: Substrate specificity in short-chain analogues at the active site of human synovial phospholipase A2. J. Med. Chem (1994) 37(24): 4118–4129.
   PubMedGoogle Scholar
• BEATON FIG, BENNION C, CONNOLLY S, COOK AR, GENSMANTEL NP, HALLAM C, HARDY K, HITCHIN B, JACKSON CG, ROBINSON OH: Discovery of new non-phospholipid inhibitors of the secretory phospholi-pases 112. J. Med. Chem. (1994) 37(5): 557–559.
   PubMedGoogle Scholar
• LEMAHIEU RA, CARSON M, HAN R-J, MADISON VS, HOPE WC, CHEN T, MORGAN DW, HENDRICKSON HS: N-(Car-boxymethyD-N-[3,5-bis(decyloxy)phenyftlycine (Ro 23-9358): A potent inhibitor of secretory phospholi-pases A2 with anti-inflammatory activity. J. Med. Chem. (1993) 36(20): 3029–3031.
   PubMedGoogle Scholar
• DE HAAS Gil, DIJKMAN R, RANSAC S, VERGER R: Competi-tive inhibition of lipolytic enzymes. IV. Structural de-tails of acylamino phospholipid analogues important for the potent Inhibitory effects on pancreatic phos-pholipase A. Biochim. Biophys. Acta (1990) 1046(3): 249–257
   Google Scholar
• BONSEN PPM, DE HAAS GH, PIETERSON WA, VAN DEENEN LLM: Studies on PLA2 and its zymogen from porcine pancreas. IV. The influence of chemical modi-fications of the lethicin structure on substrate proper-ties. Biochim. Biophys. Acta (1972) 270: 364–382.
   Google Scholar
• PISAEBARRO MT, ORTIZ AR, PALOMER A, CABRE F, GAR-CIA L, WADE RC, GAGO F, MAULEON D, CARGANICO G: Rational modification of human synovial fluid phos-pholipase A2 inhibitors. J. Med. Chem. (1994) 37(3): 337–341.
   PubMedGoogle Scholar
• SNYDER D: Novel inhibitors of secretory phospholipase A2. Oral presentation at 19th Meeting of the British Inflammation Research Association, Glasgow, UK (August 1994). Elegant use of iterative protein crystal structure/molecular modelling techniques in drug design.
   Google Scholar
• KAPLAN L, WEISS J, ELSBACH P: Low concentrations of inclomethacin inhibit phospholipase A2 of rabbit poly-morphonuclear leukocytes. Proc. Natl. Acad. Sci. USA (1978) 75: 2955–2958.
   PubMed Web of Science ®Google Scholar
• GLASER KB, CARLSON RP, SUNG A, BAUER J, LOCK Y-W, HOLLOWAY D, STURM R, HARTMAN D, WALTER T, WOEP-PEL S, HOWELL R, GRAY W, GRIMES D, KUBRAK D, BANKER A, KREFT A, WEICHMAN BM: Pharmacological characterisation of WAY-121,520: A potent anti-inflam-matory indomethacin-based inhibitor of 5-lipoxy-genase (5-L0)/phospholipase A2 (PLA2). Agents and Actions (1993) Special Conference Issue 39: C30–C32.
   Google Scholar
• KREFT A, NELSON J, MUSSER J, FAILLI A, SHAH U, KUBRAK D, BANKER A, STEFFAN R, SCHIEHSER G, STURM R, HOL-LOWAY D, BAUER J, SUNG M-L, MARSHALL L, GLASER KB: Structure-activity relationships leading to WAY-121,520, a Iris aryl-type, indomethacin-based, phos-pholipase A2 (PLA2)/leukotriene biosynthesis Inhibitor. Agents and Actions (1993) Special Conference Issue 39: C33–C35.
   Google Scholar
• BURKE JR, GREGOR KR, TRAMPOSCH KM: Mechanism of inhibition of human nonpancreatic secreted phos-pholipase Az by the anti-inflammatory agent BMS-181162. J. Biol. Chem. (1995) 270(1): 274–280.
   PubMedGoogle Scholar
• WILSON T: Gravidin: An endogenous inhibitor of phos-pholipase A2. Gen. Pharmac. (1993) 24(6): 1311–1318.
   PubMedGoogle Scholar